Home
In this issue
April 21, 2014

Andrew Silow-Carroll: Passoverkill? Suggestions to make next year's seders even more culturally sensitive

Sara Israelsen Hartley: Seeking the Divine: An ancient connection in a new context

Christine M. Flowers: Priest's execution in Syria should be call to action

Courtnie Erickson: How to help kids accept the poor decisions of others

Lizette Borreli: A Glass Of Milk A Day Keeps Knee Arthritis At Bay

Lizette Borreli: 5 Health Conditions Your Breath Knows Before You Do

The Kosher Gourmet by Betty Rosbottom Coconut Walnut Bars' golden brown morsels are a beautifully balanced delectable delight

April 18, 2014

Rabbi Yonason Goldson: Clarifying one of the greatest philosophical conundrums in theology

Caroline B. Glick: The disappearance of US will

Megan Wallgren: 10 things I've learned from my teenagers

Lizette Borreli: Green Tea Boosts Brain Power, May Help Treat Dementia

John Ericson: Trying hard to be 'positive' but never succeeding? Blame Your Brain

The Kosher Gourmet by Julie Rothman Almondy, flourless torta del re (Italian king's cake), has royal roots, is simple to make, . . . but devour it because it's simply delicious

April 14, 2014

Rabbi Dr Naftali Brawer: Passover frees us from the tyranny of time

Greg Crosby: Passing Over Religion

Eric Schulzke: First degree: How America really recovered from a murder epidemic

Georgia Lee: When love is not enough: Teaching your kids about the realities of adult relationships

Cameron Huddleston: Freebies for Your Lawn and Garden

Gordon Pape: How you can tell if your financial adviser is setting you up for potential ruin

Dana Dovey: Up to 500,000 people die each year from hepatitis C-related liver disease. New Treatment Has Over 90% Success Rate

Justin Caba: Eating Watermelon Can Help Control High Blood Pressure

The Kosher Gourmet by Joshua E. London and Lou Marmon Don't dare pass over these Pesach picks for Manischewitz!

April 11, 2014

Rabbi Hillel Goldberg: Silence is much more than golden

Caroline B. Glick: Forgetting freedom at Passover

Susan Swann: How to value a child for who he is, not just what he does

Cameron Huddleston: 7 Financial Tasks You Should Tackle Right Now

Sandra Block and Lisa Gerstner: How to Profit From Your Passion

Susan Scutti: A Simple Blood Test Might Soon Diagnose Cancer

Chris Weller: Have A Slow Metabolism? Let Science Speed It Up For You

The Kosher Gourmet by Diane Rossen Worthington Whitefish Terrine: A French take on gefilte fish

April 9, 2014

Jonathan Tobin: Why Did Kerry Lie About Israeli Blame?

Samuel G. Freedman: A resolution 70 years later for a father's unsettling legacy of ashes from Dachau

Jessica Ivins: A resolution 70 years later for a father's unsettling legacy of ashes from Dachau

Kim Giles: Asking for help is not weakness

Kathy Kristof and Barbara Hoch Marcus: 7 Great Growth Israeli Stocks

Matthew Mientka: How Beans, Peas, And Chickpeas Cleanse Bad Cholesterol and Lowers Risk of Heart Disease

Sabrina Bachai: 5 At-Home Treatments For Headaches

The Kosher Gourmet by Daniel Neman Have yourself a matzo ball: The secrets bubby never told you and recipes she could have never imagined

April 8, 2014

Lori Nawyn: At Your Wit's End and Back: Finding Peace

Susan B. Garland and Rachel L. Sheedy: Strategies Married Couples Can Use to Boost Benefits

David Muhlbaum: Smart Tax Deductions Non-Itemizers Can Claim

Jill Weisenberger, M.S., R.D.N., C.D.E : Before You Lose Your Mental Edge

Dana Dovey: Coffee Drinkers Rejoice! Your Cup Of Joe Can Prevent Death From Liver Disease

Chris Weller: Electric 'Thinking Cap' Puts Your Brain Power Into High Gear

The Kosher Gourmet by Marlene Parrish A gift of hazelnuts keeps giving --- for a variety of nutty recipes: Entree, side, soup, dessert

April 4, 2014

Rabbi David Gutterman: The Word for Nothing Means Everything

Charles Krauthammer: Kerry's folly, Chapter 3

Amy Peterson: A life of love: How to build lasting relationships with your children

John Ericson: Older Women: Save Your Heart, Prevent Stroke Don't Drink Diet

John Ericson: Why 50 million Americans will still have spring allergies after taking meds

Cameron Huddleston: Best and Worst Buys of April 2014

Stacy Rapacon: Great Mutual Funds for Young Investors

Sarah Boesveld: Teacher keeps promise to mail thousands of former students letters written by their past selves

The Kosher Gourmet by Sharon Thompson Anyone can make a salad, you say. But can they make a great salad? (SECRETS, TESTED TECHNIQUES + 4 RECIPES, INCLUDING DRESSINGS)

April 2, 2014

Paul Greenberg: Death and joy in the spring

Dan Barry: Should South Carolina Jews be forced to maintain this chimney built by Germans serving the Nazis?

Mayra Bitsko: Save me! An alien took over my child's personality

Frank Clayton: Get happy: 20 scientifically proven happiness activities

Susan Scutti: It's Genetic! Obesity and the 'Carb Breakdown' Gene

Lecia Bushak: Why Hand Sanitizer May Actually Harm Your Health

Stacy Rapacon: Great Funds You Can Own for $500 or Less

Cameron Huddleston: 7 Ways to Save on Home Decor

The Kosher Gourmet by Steve Petusevsky Exploring ingredients as edible-stuffed containers (TWO RECIPES + TIPS & TECHINQUES)

Jewish World Review

7 Stocks the Bull Market Left Behind

By Tom Petruno






JewishWorldReview.com | These are frustrating times for bargain-hunting investors, especially those seeking deals in U.S. stocks. Not much is cheap by traditional value standards, with Standard & Poor's 500-stock index priced at about 15 times estimated 2014 earnings. And in most instances the stocks that look the cheapest statistically are highly speculative.

As is the case with every bull market, though, not every stock has been bid up to the stratosphere. Look carefully and you can find companies that are reasonably valued compared with the overall market and that are industry leaders with established franchises, rich assets and attractive long-term prospects.

If you're reluctant to buy anything at current prices, you might at least want to put these seven stocks on your watch list. Any sharp selloff would be an opportunity.

American International Group
52-week price range: $36.68-$53.33

Price-earnings ratio: 12

Dividend yield: 1.0%

Let's start with an idea that may repulse many Americans but that should tantalize bargain hunters. The near-collapse of AIG (AIG) in 2008 necessitated a $182 billion bailout by the Federal Reserve and the Treasury. Now, disdain for the insurance giant is keeping the stock cheap. Not only is AIG's P/E well below the market's, but the stock trades for 27% below the company's book value (assets minus liabilities) of $69 per share.

The company has fully repaid the Fed and the Treasury, with interest. CEO Robert Benmosche, who took over in 2009, has slashed costs, sold off unrelated businesses, such as an aircraft-leasing unit, and taken AIG back to its roots as a major North American provider of life and property-casualty insurance. AIG has gone from its deathbed in 2008 to posting after-tax operating income of $6.8 billion, or $4.56 a share, in 2013.

The risks? The company's property-casualty business lags many of its rivals in profitability, in part because of high expenses. Any major natural disaster could slam AIG and other insurers. So could rising interest rates (by devaluing bond holdings). Benmosche acknowledges that AIG has more restructuring to do. But in a sign of confidence, the company announced in February a 25% dividend boost, to an annual rate of 50 cents a share.

Deere & Co.
52-week price range: $79.50-$93.88

Price-earnings ratio: 10

Dividend yield: 2.4%

If you believe that one of the hallmarks of smart value investing is going against the crowd, you ought to love Deere (DE) , the dominant seller of farm equipment in North America. Out of 22 Wall Street analysts who cover the company, 19 advise selling or holding (the latter often being a polite way of saying sell). Just three think the stock is a buy.

What's the problem? With corn and wheat prices down sharply over the past year, Wall Street is pessimistic about farmers' equipment spending in 2014. So analysts see Deere's earnings slipping to $8.41 per share in the fiscal year that ends this October, down from $9.09 the previous year.

But if you can look out a few years, you'll see Deere has set ambitious goals. Given surging food demand with the rising world population, the company is making a major push to boost foreign sales, which now account for just one-third of its total. As Morningstar notes, "Large populations in areas such as China, India and Brazil will require more-complex -- and more-costly -- agricultural equipment to improve crop yields over a limited amount of acreage." What's more, Deere continues to be aggressive in returning cash to shareholders by buying back stock and raising its dividend.

Ford Motor
52-week price range: $12.10-$18.02

Price-earnings ratio: 11

Dividend yield: 3.2%

Ford Motor (F) today is perhaps the classic value stock: It's cheap, but it also demands patience from shareholders. The auto titan warned in December that 2014 earnings would be weak compared with 2013 results, as the revitalized firm spends heavily to introduce 23 new or upgraded models, including a new lightweight aluminum model of the wildly popular F-150 truck.

The payoff is expected to materialize in 2015. Analysts see Ford's earnings declining to $1.36 per share this year from $1.76 last year, then surging to $1.92 in 2015. The stock, down 15% from its 52-week high, sells for 8 times the 2015 estimate.

Unless you think the global economy is headed for a new recession, Ford's prospects appear bright. The company signaled its confidence by announcing a 25% dividend boost in January. With a yield of 3.2%, compared with 2% for the average blue-chip stock, Ford offers a healthy cash payout while you wait for the market to look beyond this transition year.

KLA-Tencor
52-week price range: $50.23-$67.05

Price-earnings ratio: 14

Dividend yield: 2.8%

Value stock investors know that they may have to wait a while for a catalyst to spark other investors' interest. For KLA-Tencor (KLAC), a maker of semiconductor-manufacturing equipment, that catalyst may be here: an expected upturn in the chip industry capital-spending cycle.

The company is the leading producer of equipment that measures and detects defects during chip production, allowing problems to be identified and fixed. As chips become more complex and are used to power ever-faster and smarter mobile devices, "The number of process steps requiring inspection and measurement is increasing," KLA-Tencor CEO Richard Wallace told investors in January. The company, with about $3 billion in annual sales, projects chip industry capital spending to rise a healthy 10% in 2014.

Analysts expect KLA-Tencor's earnings to hit $3.79 per share in the fiscal year that ends in June 2014, then to jump 24%, to $4.69 per share, the following year. The stock now sells for about 14 times fiscal 2015 earnings, while yielding nearly 3% -- two attractive numbers for value hunters. Investors in KLA-Tencor are in good company: Among the biggest owners of the shares are savvy stock pickers American Funds, Primecap

Management and Artisan Partners.


FREE SUBSCRIPTION TO INFLUENTIAL NEWSLETTER

Every weekday JewishWorldReview.com publishes what many in the media and Washington consider "must-reading". HUNDREDS of columnists and cartoonists regularly appear. Sign up for the daily update. It's free. Just click here.


Medtronic
52-week price range: $43.51-$60.93

Price-earnings ratio: 14*

Dividend yield: 2.0%

Medtronic (MDT), a world leader in medical devices, is an example of a company whose image as a hot growth name has faded over time. The stock is no higher than it was in 2005, yet earnings have doubled since then. That's a cue for value hunters.

Medtronic makes a wide array of devices, including pacemakers, artificial heart valves, insulin pumps and artificial spinal discs. Sales are expected to reach a record $17 billion in the current fiscal year, which ends in April. But Wall Street has had a number of concerns lately. One is Medtronic's apparent failure with a new device aimed at lowering chronic high blood pressure by dulling nerve endings in the kidneys. Analysts had high hopes for the technique. Second, a jury in January ordered Medtronic to pay archrival Edwards Lifesciences $394 million for patent infringement on a new artificial heart valve that is implanted without surgery.

Still, Medtronic now has government approval to launch its version of the valve in the U.S., taking on Edwards. In the long run, Medtronic remains an attractive play on medical innovation and the rising health care needs of aging baby-boomers.

*Based on estimated earnings through January 31, 2015.

Ross Stores
52-week price range: $54.86-$81.99

Price-earnings ratio: 16*

Dividend yield: 1.0%

Ross Stores (ROST) has built the largest off-price retail chain in the U.S., with 1,285 locations nationwide selling brand-name goods at a discount. Its success in that niche fueled huge gains in its stock over the past decade, with the price up twenty-fold since 2000. But even Ross has been hit by weak consumer spending in recent months. The company warned in November that same-store sales (revenue from stores open at least one year) in the quarter that ended in January 2014 would be up as little as 1% from the same period a year earlier. That has driven the shares down 17% from their 52-week high.

Yet as smaller off-price retail competitors such as Filene's Basement and Loehmann's die off -- and major chains such as Sears and J.C. Penney struggle -- Ross's long-term prospects should improve. Morningstar calls the company "one of the more compelling long-term ideas in the apparel retail space" and thinks Wall Street has undervalued the chain's growth potential.

Two other draws: Ross has little debt and a recent history of strong dividend increases. The payout has surged at an annualized rate of 25% since 2008. When Bloomberg News in January ranked S&P 500 stocks for expected dividend growth over the next three years, Ross was ninth on the list, with estimated growth of 19.5% a year.

*Based on estimated earnings through January 31, 2015.

Whiting Petroleum

52-week high/low: $42.44-$70.57

Price-earnings ratio: 16

Dividend yield: 0%

The bull market has rolled along without Whiting Petroleum (WLL) since 2011, when the shares peaked in the mid $70s. They have traded erratically since and have pulled back again in recent months. The problem? For one thing, Wall Street doesn't believe the company has yet lived up to the hype as one of the largest oil producers in the Bakken shale-oil field of North Dakota.

Whiting has more than doubled its annual revenue since 2008, to about $2.8 billion, but ballooning expenses have held earnings to a much more modest 40% rise. The company doesn't pay cash dividends. And some investors have been exasperated as rumors of a buyout of Whiting by a bigger energy company periodically boost the stock, then fade away.

Still, at current valuation levels, the shares are a compelling way to play the continuing oil boom in the Bakken region, where Whiting remains an aggressive driller. The firm also has exciting prospects in a new area of drilling in northern Colorado, in the so-called Niobrara shale formation. Ultimately, this is a bet on the U.S. moving closer to energy independence -- and on crude prices staying high enough to keep shale-oil drilling lucrative.

Sign up for the daily JWR update. It's free. Just click here.

Interested in a private Judaic studies instructor — for free? Let us know by clicking here.

Tom Petruno is a Contributing Writer for Kiplinger's Personal Finance magazine.



All contents copyright 2013 The Kiplinger Washington Editors, Inc. Distributed by Tribune Content Agency, LLC

Quantcast